The National Institutes of Health (NIH) has announced an investment of more than $150 million to develop and scale research methods that more closely simulate human biology. This initiative, known as the Complement Animal Research in Experimentation (Complement-ARIE) program, focuses on the development, implementation, and standardization of new approach methodologies (NAMs). These lab-based or computer-based methods are designed to provide more predictive models of human disease than traditional animal research.
Standardizing new approach methodologies for the laboratory
The Complement-ARIE program seeks to create a comprehensive repertoire of human-focused methods to improve successful clinical translation. According to Nicole Kleinstreuer, PhD, NIH deputy director for program coordination, planning, and strategic initiatives, these sophisticated models will allow researchers to answer questions that remain beyond the reach of current research models.
To facilitate this transition, the NIH is establishing several key infrastructure components:
- Technology development centers (TDCs) to advance NAMs in areas with significant scientific and regulatory needs, such as cardiac disease, neurological disorders, and rare diseases
- A NAMs data hub and coordinating center (NDHCC) to streamline data sharing and the development of industry standards
- A validation and qualification network (VQN) to ensure these new tools are reliable, marketable, and ready for regulatory clearance
The VQN is a public-private partnership involving the Foundation for the National Institutes of Health, designed to prepare these technologies for the rigorous demands of regulatory processes.
Pilot projects and the shift toward human-based research
The program has already identified four initial pilot projects to lead the way in NAMs implementation. These projects focus on critical health and safety areas: preterm birth, developmental neurotoxicity, inhalation toxicity, and acute oral toxicity.
Furthermore, the NIH has launched a $7 million NAMs Reduction to Practice Challenge in collaboration with the Food and Drug Administration and the Environmental Protection Agency. This challenge tasks research teams with demonstrating the viability of human-based NAMs within a three-year period, with the goal of delivering these tools to the VQN for broader application.
Enhancing laboratory predictive modeling and data integrity
This shift represents a significant change in how research workflows and data validation are handled. As the industry moves toward more sophisticated human-based models, the emphasis on standardized data through the NDHCC will be vital for maintaining gold-standard research levels. These investments suggest a future where the reliance on animal models is significantly reduced in favor of high-fidelity, human-relevant technologies that can be more easily qualified by regulatory bodies.
Managing the transition to these new methodologies will require a focus on specialized training and the integration of new digital infrastructure. The focus on marketable and reliable NAMs ensures that the tools being developed are not just theoretical but are practical instruments intended for use in professional laboratory settings.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
